Opa interacting protein 5 acts as an oncogene in bladder cancer
Authors:
- 27 July 2017
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 143 (11) , 2221-2233
Abstract
Purpose To explore the biological functions and mechanism of Opa interacting protein 5 (OIP5) in bladder cancer (BC). Methods We investigated the expression of OIP5 in BC through immunohistochemical staining (IHC) and its correlation with clinicopathologic features of BC patients. Moreover, knockdown of OIP5 was performed in BC cell lines and colony formation capacity, cell growth curve, cell cycle phase and cell apoptosis assay was applied for investigating the roles of OIP5 in BC. Moreover, the expression of OIP5 was validated through the Cancer Genome Atlas (TCGA) database. The diagnosis value of OIP5 was accessed by receiver operating characteristic (ROC) analysis in TCGA database. Results The expression of OIP5 in BC tissues was significantly higher than that in adjacent non-tumor tissues and bladder mucosa tissues with chronic cystitis. Higher protein expression level of OIP5 predicted shorter survival time in patients with BC, which was significantly correlated with larger tumor size, high-grade tumor and advanced T classification. The expression of OIP5 was considerably decreased after lentivirus infection both at mRNA and protein levels. Functional assay displayed that silencing of OIP5 inhibited colony formation capacity and cell growth in BC cell lines. Cell cycle assays indicated that suppressed OIP5 disturbed the balance of the cell cycle in BC cell lines, which increased the cell population of the G1 phase and decreased the cell population of the S phase. Furthermore, knockdown of OIP5 expression enhanced cell apoptosis process. The expression of OIP5 was significantly up-regulated in BC compared with adjacent non-tumor tissues based on TCGA database. OIP5 had the potential diagnostic value for BC. Conclusions Our work demonstrated that OIP5 might function as an oncogene to promote colony formation capacity and cell growth, arrest cell cycle and suppress cell apoptosis in bladder cancer.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81671549)
- National Natural Science Foundation of China (No. 81273266)
- National Natural Science Foundation of China (No. 81272839, No. 81472401)
This publication has 30 references indexed in Scilit:
- FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathwayOncotarget, 2016
- Systemic, perioperative management of muscle-invasive bladder cancer and future horizonsNature Reviews Clinical Oncology, 2016
- Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analysesEuropean Journal of Epidemiology, 2016
- Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.2015
- International Variations in Bladder Cancer Incidence and MortalityEuropean Urology, 2014
- Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression patternMedical Oncology, 2013
- MAGE‐A10 cancer/testis antigen is highly expressed in high‐grade non‐muscle‐invasive bladder carcinomasInternational Journal of Cancer, 2012
- LAP2α-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exitJournal of Cell Science, 2007
- Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approachesBlood, 2006
- Using the yeast two‐hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growthMolecular Microbiology, 1998